Lorcis Vianath-ith-Vianne & Selves Pty., Bonded Commercial Obligators, to Mettáre viKoruaz, viKoruaz, viHanic, and Siblings, greetings.
With regard to your communication of the 3rd inst. with our client, Ordene Psychedesign, ICC:
Without prejudice, our client expresses regret at your client’s dissatisfaction with the performance of their product, AnAddiction™. Nevertheless, we beg to point out that;
Firstly, the product did function as designed. By your client’s own admission as stated in your communication, the modification of the neural loops of the basal ganglia limbic pathways by the AnAddiction™ nanomachines produced an absence of the psychological addiction to catecholamine rríyek-4/CrystalFugue™ which, as you indicate, was your client’s purpose in purchasing this product.
Secondly, further without prejudice to the validity of the claims that you make regarding the effect of the product, post-usage, upon your client’s personal relationships (p. 2-4 of your complaint) and religious faith (p. 5), our client freely stipulates that, should such behaviors extend to the degree of behavioral addictions in a clinical sense (ref. Manual of Mental Diagnostics, 271st ed., p. 479), the AnAddiction™ product would also remove the limbic pathways promoting such behaviors.
However, we would draw your attention to clause 14 in the purchase contract-waiver, signed by your client before purchasing the AnAddiction™ product, which states that the product should only be used on brains reflecting otherwise healthy/optimal mind-states, in a clinical sense (ref. Manual of Mental Diagnostics, 271st ed., p. 29), for the removal of specific single addictions or general addiction, and in particular to subclause 14(a), which makes specific mention of AnAddiction™’s indistinctive removal of all addiction-promotor loops exceeding the clinically determined indicator level, and refers you for more details to the relevant case studies (Identification of Pathological Promotor Loops in the Sophont Brain, Journal of Neuronanopharmacology, Imp. U. of Almeä Press, v. 517) and the AnAddiction™ clinical trials. Per clause 14, our client does not recommend and specifically disclaims liability for use of AnAddiction™ on non-healthy/optimal cases except under the supervision of a professional bonded psychedesigner.
As such, we would advise you that our client does not intend to offer a settlement with regard to your proposed suit, and it is our opinion that the claims you cite are meritless under applicable commercial and contract law, and that our client will prevail should this matter proceed to litigation.
Lorcis Tridecimus Vianath-ith-Vianne, obl.
for and on behalf of
Lorcis Vianath-ith-Vianne & Selves Pty., Bonded Commercial Obligators
Ordene Psychedesign, ICC